Charles Blanke
Chair, SWOG · Oregon Health & Science University
Credentials: · · · ·
History
- Present
SWOG Department · Oregon Health & Science University
1984–1988
Research
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
New England Journal of Medicine · 2002 · 3,431 citations
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group
New England Journal of Medicine · 2000 · 2,536 citations
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor
Journal of Clinical Oncology · 2003 · 1,800 citations
37 papers
29 papers
- RG
24 papers
- CC
20 papers
- CR
20 papers
20 papers
- ES
19 papers
19 papers
Grants
- 2014–2027
National Cancer Institute · UG1
Contact PI · $80.6M · Oregon Health & Science University
- 2014–2026
SWOG Network Group Operations Center of the NCTN
National Cancer Institute · U10
Contact PI · $130.3M · University of California at Davis
- 1983–2016
SWOG Community Clinical Oncology Program Research Base
National Cancer Institute · U10
Contact PI · $7M · Oregon Health & Science University
- 1981–2015
Southwest Oncology Group Treatment Grant
National Cancer Institute · U10
Contact PI · $12.6M · Oregon Health & Science University
Clinical trials
- 2008–2015
Principal investigator · Terminated · Phase 3
National Cancer Institute (NCI)
- 2007–2011
Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal Tumors
Principal investigator · Terminated · Phase 1
Vanderbilt-Ingram Cancer Center
- 2004
Principal investigator · Terminated · Phase 3
National Cancer Institute (NCI)
- 2002–2006
Calcitriol and Docetaxel in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer
Principal investigator · Completed · Phase 2
OHSU Knight Cancer Institute